Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Synedgen Inc. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct art units, indicating a relatively diverse technical focus for the company's active filings. The prosecution involves 2 distinct examiners, providing a spread of administrative oversight and ensuring that the company's intellectual property is being reviewed from multiple perspectives within the patent office.
JONATHAN S LAU is identified as the busiest examiner for the portfolio, currently managing 1 pending office action. This indicates that the company's 2 pending office actions are distributed among the examiners involved, with no individual examiner handling the entire workload. For a practitioner, this distribution across 2 distinct art units and 2 distinct examiners suggests a balanced prosecution strategy. It avoids the risks associated with having a portfolio's success tied to a specialized unit within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LAU, JONATHAN S | 1 | 63.7% | -17.3% |
| BAKSHI, PANCHAM | 1 | 76.8% | +30.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17669766 | COMPOSITIONS AND METHODS OF THEIR USE | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18421551 | DERIVATIZED CHITOSAN POLYMERS AND METHODS OF TREATING VASCULAR DISORDERS | LAU, JONATHAN S | 1693 | §103DP | Non-Final OA | 60d overdue | Pending | Jan 24, 2024 |
| 17669766 | COMPOSITIONS AND METHODS OF THEIR USE | BAKSHI, PANCHAM | 1623 | §103DP | Non-Final OA | — | Pending | Feb 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial